Q3 EPS Forecast for PTC Therapeutics Decreased by Analyst

Key Points

• Leerink Partnrs has revised its forecast for PTC Therapeutics, expecting Q3 2025 earnings to decrease to ($1.14) EPS, down from a previous estimate of ($1.04).
• In addition to the earnings downgrade, several analysts have also adjusted their ratings and price targets for PTC Therapeutics, with the average target price now set at $65.00.
• PTC Therapeutics recently reported a significant earnings beat with $10.04 EPS for the last quarter, though this was accompanied by a 9.6% drop in revenue year-over-year.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for PTC Therapeutics in a research report issued on Wednesday, July 23rd. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($1.14) per share for the quarter, down from their previous forecast of ($1.04). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics' Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at $8.61 EPS and FY2026 earnings at ($3.12) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping the consensus estimate of $0.85 by $9.19. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. During the same period in the previous year, the business earned ($1.20) earnings per share. The firm's revenue was down 9.6% on a year-over-year basis.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald boosted their target price on PTC Therapeutics from $112.00 to $120.00 and gave the stock an "overweight" rating in a research report on Tuesday. UBS Group upped their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday. JPMorgan Chase & Co. cut their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Bank of America upped their price objective on PTC Therapeutics from $68.00 to $84.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wall Street Zen lowered PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $69.38.

PTC Therapeutics Stock Performance

PTC Therapeutics stock traded up $0.57 during midday trading on Monday, hitting $51.51. 205,992 shares of the company's stock were exchanged, compared to its average volume of 1,039,994. PTC Therapeutics has a 52-week low of $29.01 and a 52-week high of $58.38. The stock has a 50-day moving average price of $48.95 and a two-hundred day moving average price of $48.58. The company has a market cap of $4.08 billion, a P/E ratio of 7.92 and a beta of 0.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in shares of PTC Therapeutics by 424.4% in the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 522 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of PTC Therapeutics by 545.5% in the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 551 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 320 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of PTC Therapeutics by 86.3% in the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 441 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of PTC Therapeutics in the 1st quarter worth approximately $61,000.

Insider Buying and Selling

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 1,929 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $46.18, for a total transaction of $89,081.22. Following the completion of the transaction, the vice president owned 103,901 shares of the company's stock, valued at $4,798,148.18. This represents a 1.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total value of $124,441.36. Following the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at $3,557,163.20. The trade was a 3.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,328 shares of company stock valued at $254,158 in the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.